Peptide p277

Drug Profile

Peptide p277

Alternative Names: AVE-0277; DiaPep-277; DiaPep277

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Andromeda Biotech; DeveloGen
  • Class Antihyperglycaemics; Heat shock proteins; Peptide fragments; Peptide vaccines
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Suspended Latent autoimmune diabetes in adults; Type 1 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2016 Andromeda Biotech completes a phase III extension trial for Type-1 diabetes mellitus in Israel (NCT00644501)
  • 17 Feb 2015 Hyperion CBI and Yeda enter into a final agreement in relation to the development of peptide p277
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top